Live Breaking News & Updates on High Risk Hospitalized

Stay updated with breaking news from High risk hospitalized. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

11.08.2022 - -Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022- -The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will . ....

United States , United Kingdom , Mitchell Steiner , Samuel Fisch , Sexual Health Division , Ar Prostate Cancer Program , European Medicines Agency Emergency Task , Company To Host Investor Conference Call , Breast Cancer Program , European Union , Veru Inc , Massachusetts Medical Society , Goodrx Inc , Patients For Emergency Use In European Union , Data Monitoring Committee , Company Form , Exchange Commission , Corporate Communications , Healthcare Products Regulatory Agency , European Medicines Agency , Emergency Task Force Initiated Review , Sabizabulin Treatment , Emergency Use , New England Journal , Medicine Evidence Published Phase , Trial Results Demonstrating ,

Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
Veru Inc.May 12, 2021 GMT
First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin
(VERU-111) in High Risk Hospitalized COVID-19 Patients
New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dosing Combination for BPH; PDUFA Date December 2021
Company Poised to Enroll First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin for Metastatic Castration and AR Targeting Agent Resistant Prostate Cancer Later this Month ....

United States , Mitchell Steiner , Sam Fisch , Company Sexual Health Business , Sexual Health , Company Anticipates Enrolling First Patient In Phase , Sexual Health Business , Health Company Business , Company To Host Investor Conference Call , Exchange Commission , Company Form , Legacy Female Health Business , Company Female Health Division , Veru Inc , Health Company , High Risk Hospitalized , New Drug Application Accepted , Oral Dosing Combination , Company Poised , Enroll First Patient , Metastatic Castration , Agent Resistant Prostate Cancer Later , Company Anticipates Enrolling First Patient , Androgen Deprivation Therapy , Advanced Prostate Cancer Later , Host Investor Conference Call Today ,